Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: raum t. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605-10. doi: 10.1073/pnas.1000976107. Epub 2010 Jun 28. Proc Natl Acad Sci U S A. 2010. PMID: 20616015 Free PMC article.
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA. Brischwein K, et al. Among authors: raum t. Mol Immunol. 2006 Mar;43(8):1129-43. doi: 10.1016/j.molimm.2005.07.034. Epub 2005 Sep 1. Mol Immunol. 2006. PMID: 16139892
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: raum t. J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70. J Immunother. 2009. PMID: 19342971
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M. Amann M, et al. Among authors: raum t. J Immunother. 2009 Jun;32(5):452-64. doi: 10.1097/CJI.0b013e3181a1c097. J Immunother. 2009. PMID: 19609237
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.
Steigerwald J, Raum T, Pflanz S, Cierpka R, Mangold S, Rau D, Hoffmann P, Kvesic M, Zube C, Linnerbauer S, Lumsden J, Sriskandarajah M, Kufer P, Baeuerle PA, Volkland J. Steigerwald J, et al. Among authors: raum t. MAbs. 2009 Mar-Apr;1(2):115-27. doi: 10.4161/mabs.1.2.7630. Epub 2009 Mar 11. MAbs. 2009. PMID: 20061825 Free PMC article.
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T. Münz M, et al. Among authors: raum t. Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44. Cancer Cell Int. 2010. PMID: 21044305 Free PMC article.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P. Friedrich M, et al. Among authors: raum t. Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5. Mol Cancer Ther. 2012. PMID: 23041545
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B. Friedrich M, et al. Among authors: raum t. Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27. Mol Cancer Ther. 2014. PMID: 24674885
25 results